New hope for tough cancers: testing a targeted drug
NCT ID NCT06243354
Summary
This study is testing a new drug, HYP-2090PTSA, for people with advanced solid tumors that have a specific genetic change called a KRAS mutation. The first part aims to find a safe and effective dose. The second part will explore how well the drug works for certain cancers with a specific KRAS mutation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TOLERABILITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Provincial Cancer Hospital
RECRUITINGFuzhou, Fujian, 350000, China
Contact
-
Hunan Provincial Cancer Hospital
NOT_YET_RECRUITINGChangsha, Hunan, 410000, China
Contact
-
Shandong Provincial Cancer Hospital
NOT_YET_RECRUITINGJinan, Shandong, 250000, China
Contact
-
Shanghai Pulmonary Hospital
RECRUITINGShanghai, Shanghai Municipality, 200000, China
Contact
-
The first Hospital of China Medical University
NOT_YET_RECRUITINGShenyang, Liaoning, 110000, China
Contact
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610000, China
Contact
Conditions
Explore the condition pages connected to this study.